M. A Bayesian approach for estimating detection times in horses: exploring the pharmacokinetics of a urinary acepromazine metabolite. J. vet. Pharmacol. Therap. doi: 10.1111Therap. doi: 10. /j.1365Therap. doi: 10. -2885Therap. doi: 10. .2012 We describe the population pharmacokinetics of an acepromazine (ACP) metabolite (2-(1-hydroxyethyl)promazine) (HEPS) in horses for the estimation of likely detection times in plasma and urine. ACP (30 mg) was administered to 12 horses, and blood and urine samples were taken at frequent intervals for chemical analysis. A Bayesian hierarchical model was fitted to describe concentration-time data and cumulative urine amounts for HEPS. The metabolite HEPS was modelled separately from the parent ACP as the half-life of the parent was considerably less than that of the metabolite. The clearance (Cl/F PM ) and volume of distribution (V/F PM ), scaled by the fraction of parent converted to metabolite, were estimated as 769 L/h and 6874 L, respectively. For a typical horse in the study, after receiving 30 mg of ACP, the upper limit of the detection time was 35 h in plasma and 100 h in urine, assuming an arbitrary limit of detection of 1 lg/L and a small (%0.01) probability of detection. The model derived allowed the probability of detection to be estimated at the population level. This analysis was conducted on data collected from only 12 horses, but we assume that this is representative of the wider population.
INTRODUCTION
Acepromazine (ACP) is a phenothiazine tranquilizer commonly used in horses to reduce stress during transportation and to calm excitable horses during veterinary procedures or in training (Smith et al., 1996) . As with most therapeutic substances, ACP is prohibited in competition by most racing organizations (Chou et al., 2002) . If a sufficiently long washout period is not observed before a race after ACP has been administered, the trainer runs the risk of detection and associated penalties.
Drug screening is regulated by racing authorities who are in the process of establishing limits of detection in blood and urine for a range of therapeutic substances, based on either the parent drugs or their metabolites. These limits are being established in order to protect the integrity of the sport without adversely affecting the welfare of the horse by restricting legitimate therapeutic treatment, as discussed by Toutain (2010) . Therefore, there is interest in assembling detailed pharmacokinetic data to enable the rational setting of analytical detection limits and corresponding withdrawal times for particular prohibited substances.
Approaches to the detection of prohibited substances in horse racing differ from country to country, such that estimated withholding times may vary depending upon which country the horse is racing in. For example, urine samples are favoured for drug detection in Australia, whereas plasma samples are preferred in the USA. Nevertheless, both countries consider a drug test to be positive if the parent compound or one of its metabolites is detected on race day. Therefore, to provide precise estimates of withholding times, an understanding of the metabolism and the renal excretion of the drug is required. This understanding can be facilitated through the modelling of the pharmacokinetics (PK) of the drug, that is, what the body does to the drug after administration (Benet, 1984) . In general, such models describe how the drug is metabolized and then eliminated from the body over time.
In this study, we consider ACP as the parent drug and 2-(1-hydroxyethyl)promazine (HEPS) as the principle metabolite. This leads to the consideration of a parent-metabolite model that describes the conversion of ACP to HEPS, and the elimination of both substances from the body via the urine. The individual (or horse) specific PK for ACP have been studied previously (Ballard et al., 1982; Hashem and Keller, 1993; Marroum et al., 1994) . To our knowledge, limited research has appeared in the literature in regard to the PK of HEPS, see Schneiders et al. (2012) , who suggest that detection of HEPS could be used as an indicator for the use of ACP. Furthermore, detection times are often reported in studies of a few (3-6) horses and in absolute terms (i.e. number of hours or days) with no probability values attached to them. In the present study, we sought to determine more accurate detection times by using a larger number of horses (12) and to explore a means to judge, not just the time of detection, but the probability of detection at a given time.
We developed an understanding of the PK and renal excretion of HEPS at a population level through the implementation of a Bayesian hierarchical model (BHM). Covariates were available and included breed, body weight (kg) and age (years), and these were explored as potential effects to minimize unexplained between-subject variability (BSV). Also, plasma concentrations were subject to measurement error as two measurements were taken for each sample, and analysed separately. Given the two approaches to measure plasma concentration from each sample generally gave differing results, this source of variability needed to be considered in the model. Once a parsimonious statistical model had been developed, simulation techniques were used to estimate the detection times in plasma and urine.
ANALYTICAL METHODS
Acepromazine and HEPS were analysed by LC-MS following the extraction from blood plasma and urine using a solid-phase extraction method. To prepare the samples for analysis, aliquots were spiked with internal standards (propionylpromazine hydrochloride and HEPS-d4 maleate), then diluted with either acetic acid (urine) or acetic acid plus methanol (plasma).
The samples were centrifuged to remove proteinaceous material before the supernatant fractions were loaded onto IST Isolute HCX solid-phase extraction cartridges that had previously been conditioned with methanol and acetic acid. The cartridges were washed with acetic acid and methanol, dried briefly and then eluted with an mixture of ethyl acetate, methanol and ammonium hydroxide. The eluates were evaporated to dryness at 60°C under a stream of nitrogen and reconstituted in isopropanol and ammonium acetate (20 mM) for analysis.
The samples were analysed using a Waters Acquity UPLC system equipped with a Waters Acquity UPLC BEH C18 analytical column and a Phenomenex Security-Guard C18 guard column interfaced to an Applied Biosystems 4000 Q-Trap mass spectrometer Melbourne, Vic., Australia. The mobile phase varied from 100% aqueous ammonium acetate to 40% ammonium acetate/60% acetonitrile, which was run as a gradient. The instrument was operated in positive ion atmospheric pressure chemical ionization (APCI) mode with ion source conditions optimized for ACP.
Calibration standards and quality control samples were prepared by spiking pooled blank equine plasma and urine with ACP maleate and HEPS maleate. The specificity of the method was assessed by analysing 12 blank equine plasma and 12 blank equine urine samples. No significant matrix interference was observed, and the calibration curves for both ACP and HEPS in plasma and urine were linear over the full calibration ranges. Correlation coefficients for ACP were 0.9889 or greater and for HEPS 0.9996 or greater in both matrices. The limit of quantification (LOQ) for both analytes in both matrices was 1 ng/mL. The limit of detection (LOD) based on a signal-to-noise ratio >3 was <1 ng/mL in all cases.
Accuracy and precision data were collated from the quality control samples prepared at low and high concentrations. The accuracy of detection (% of nominal) for ACP in plasma ranged from 95% to 109%, with a precision (% CV) of 3.6-5.3%. In urine, values for accuracy and precision for ACP detection were 89% to 104% and 4.4% to 7.7%, respectively. The corresponding values for HEPS were as follows: accuracy 88-104%, precision 6.4-7.9% (plasma); and accuracy 103-119%, precision 3.1-4.5% (urine).
DESIGN AND DATA COLLECTION
Data were collected on twelve horses (geldings) after an intravenous administration of ACP maleate equivalent to 30 mg dose of ACP, denoted as D. Injections were given into the jugular vein after the insertion of an indwelling catheter on the morning of the experiment. A summary of the 12 horses is given in Table 1 . All horses were weighed the day before drug administration and at the end of the study, and it was found that the weight of each horse had changed slightly over the duration of the study, despite being fed a diet that was designed to maintain a stable body weight. If this change was linear (this is the only change we can estimate given these data), then there was <6% change in weight across all horses. Hence, weight as a time-varying covariate was not considered because of such small changes, and the average (or median) of the two measurements was used for covariate exploration.
ACP and HEPS concentration-time data were derived from the chemical analysis (as discussed in the previous section) of blood and urine samples collected at frequent intervals; 10-mL blood samples were collected into lithium heparin vacutainers at the following time points: 0. 08, 0.17, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24 h after administration. Urine samples were collected approximately 2, 4, 6, 8, 12, 24, 36 and 48 h after administration. The horses were trained to urinate to a whistle. The urine was collected into a 2-L plastic container that was attached to each horse. Each horse also wore a specially designed harness known as a 'horse nappy' between collection times to ensure that all urine was collected. The midpoint between collection times was used as the average urine amount. Hence, the average urine amount was modelled over each of the time spans. Parent ACP was not detected in urine and hence could not be modelled. All samples were refrigerated directly after collection and stored at )20°C until analysed.
MODEL
Realistic statistical models for PK data are often complex systems incorporating auxiliary variables in hierarchies or strata. Bayesian statistical methodology provides powerful methods for modelling such data, combining prior knowledge with information from the data to yield a posterior distribution from which all inference about unknowns can be made. Unfortunately, sampling from this posterior distribution can be difficult in practice as no closed-form solution may be available. This led to the development of a collection of proven computational methods used across a wide area of applied sciences and technology. The most widely used computational method is Markov chain Monte Carlo (MCMC), a technique that can be used to sample from a target distribution (here, a posterior) that is difficult to sample from directly. This facilitates posterior inference in complex settings. A full-conditional hierarchical Bayesian analysis was undertaken using WinBUGS (Lunn et al., 2000) where MCMC techniques are used to sample from the posterior distribution of estimable parameters. Reviews of Bayesian modelling of pharmacokinetic data are given by Duffull et al. (2005) and Lunn et al. (2002) , and an example is given by Dansirikul et al. (2005) .
In our analysis, two MCMC chains were run simultaneously, each with different initial parameter estimates for each parameter. Convergence of the MCMC chains to the stationary distributions was assessed in two ways. Firstly, the Gelman and Rubin convergence diagnostic (Kass et al., 1998) was calculated for each parameter. This diagnostic essentially compares the between-chain variability with the within-chain variability. If this variability is similar, the value of the diagnostic will be close to 1. In our analysis, if values were <1.1 for all parameters, then it was assumed that the stationary distribution had been reached under this diagnostic. As a further check, the trace history for each parameter was plotted to ensure that the 'fuzzy caterpillar' was observed (Lunn et al., 1999) .
The two MCMC chains were run for 20 000 samples with the first 10 000 being discarded as a 'burn-in'. If the above convergence criteria were met, the two chains were pooled to provide samples from the stationary/posterior distribution. It is this distribution upon which all inferences were drawn.
Parent and metabolite model
The full data set consisted of ACP and HEPS plasma concentrations and urine amounts over time. Therefore, a multivariate response model needed to be derived. A full parent-metabolite model based on mass balance is given in Fig. 1 . Figure 1 shows a five-compartment parent-metabolite model. Initially, the parent (P) enters into the first of two compartments, where it can move between this compartment (P 1 ) and another (P 2 ). A two-compartment model was proposed for this part of the model as this was fitted in the analysis of ACP given by Ballard et al. (1982) , Hashem and Keller (1993) and Marroum et al. (1994) . A fraction of the parent is either converted to the metabolite (F PM ), excreted renally (F EP ) or eliminated nonrenally (1 ) F PM ) F EP ). In the second case, the triangle represents the bladder (P3), and the parent will continue to accumulate here until the horse empties the bladder. For the fraction of the parent that is converted to the metabolite (M), a fraction of M is either excreted renally (F EM ) or nonrenally (1 ) F EM ). In this first case, the metabolite accumulates in the bladder (M 2 , represented by a triangle) until the horse empties the bladder. The ks denote rate constants for movement between compartments.
A simplification of this parent-metabolite model was made. Given the half-life of the parent was considerably shorter than that of the metabolite, we can conclude that the kinetics of the metabolite were not being driven by the parent. In such cases, it should be sufficient to model the metabolite alone, particularly given we are only interested in estimating detection times for the metabolite; notably, this is a key assumption in our approach, and further research would be required to determine whether this biased our analysis. Figure 2 shows the proposed model for plasma concentration and cumulative urine amount for the metabolite only. Initially, ACP appears in compartment P 1 and is converted to HEPS that appears in M 1 (the molecular weights of ACP and HEPS are 326 and 345, respectively). Here, M 1 represents the amount of HEPS in plasma, with a fraction being excreted renally (F E ) to the bladder (M2) and a fraction excreted nonrenally (1 ) F E ). The metabolite will then accumulate in M 2 until the horse empties their bladder. 
Metabolite model
where Cl R ¼ F E Cl and Cl NR ¼ (1)F E )Cl are renal clearance and nonrenal clearance, respectively; Cl ¼ Cl R + Cl NR and V is the volume of distribution. As we only model HEPS, estimates of clearance and volume of distribution are scaled by the fraction of the parent converted to the metabolite, that is, Cl/F PM and V/F PM . To facilitate the estimation of the parameters in the model, the assumption is that F PM ¼ 1. We note, however, Ballard et al. (1982) show that approximately 50% of injected ACP binds to red blood cells. Of this 50%, an estimated fraction of 0.99 (±0.01) is converted to HEPS, see Schneiders et al. (2012) . Even though our parameterization may not reflect the true biological process, it does allow an accurate mathematical representation of the data, see Duffull et al. (2000) .
The ordinary differential equations (ODEs) that describe the kinetics of this model for the amount of the metabolite are as follows. We note that these are linear ODEs and hence can be solved analytically.
where
The above ODEs provide the structural model for the analysis. When solved, they provide predicted responses for each of the three compartments. For modelling the metabolite data, we are only interested in the solution to compartments M 1 and M 2 . Denote the predicted responses in each of these compartments as f 1 (.) and f 2 (.), respectively.
The following describes the full probabilistic model. In model development, we consider a number of alternative models in an attempt to derive a parsimonious description the multivariate data. Instead of describing all models considered, we describe a 'full' model such that all other rival models are parametrically nested within this full model.
The hierarchical structure of the probabilistic model can be described in the following stages:
represents the model prediction for the kth response on the jth measurement type on the ith individual in compartment M l , and the variance of this response is given by c ijkl ¼ r Stage 2.
behaviour and U is the measurement error variance-covariance matrix of PK parameters.
Stage 3.
log h i j log l; Z i ; X $ MVNðlog l; XÞ;
where Z i represents the covariate values for the ith individual, X the between-horse variability and l ¼ (Cl,F E ,V) ¢ the population PK parameters.
Stage 4 (priors).
r 2 add;l $Unið0; 100Þ r 2 prop;l $Unið0; 100Þ logðCl; VÞ 0 $MVNð0; 1000 Â IÞ k 12 $HNð0; 1000Þ log F E $UniðÀ300; 0Þ U $Wð0:001 Â I; 5Þ X $Wð0:001 Â I; 5Þ;
where l ¼ 1,2, and Uni(), MVN, HN and W denote the uniform, multivariate normal, half-normal and Wishart distributions, respectively. These priors were chosen to be essentially uninformative, meaning that they should have minimal influence in determining the parameter estimates when compared to the observed data. It should be noted that, when estimating F E , it is possible [through BSV and measurement error variability (MEV)] that this estimate may be larger than 1. This is impossible in Fig. 2 . A simplified pharmacokinetic model for metabolite (2-(1-hydroxyethyl)promazine) after an intravenous administration of acepromazine to horses.
practice, so the constraint min{1,F E } was imposed in the estimation. As can be seen, k 12 was assumed to be a fixedeffects parameter, so no BSV (or MEV) was estimated.
RESULTS
The observed (log) concentration-time data and accumulated urine amounts of HEPS for the 12 horses are shown in Fig. 3 . The demographic data collected for the 12 horses were breed, weight (kg) and age (years). Of the 12 horses, four were thoroughbreds and eight were standardbreds. The mean (± SD) body weight of all horses was 544 (±48) kg, and the mean (± SD) age was 8 (±2.8) years.
Structural and residual error model
The model specified in Fig. 2 was considered with additive, proportional and a mixture of additive and proportional residual errors on each of the two responses. These model fits can be compared by considering deviance, calculated as minus twice the log-likelihood. Given we typically wish to select parameter estimates that maximize the log-likelihood, we would like to select the model with the smallest deviance. However, as more parameters are included, the model will generally fit the data 'better' and will therefore result in a smaller deviance (even though this decrease may not be statistically significant). Therefore, we would ideally like to select the model that has small deviance and a small number of parameters. The results of model fits are summarized in Table 2 . The smallest median deviance can be seen for the model that has a proportional residual error term on plasma concentrations and an additive residual error on the cumulative urine amounts. Further, this model has less than or equal the number of parameters to estimate when compared with other rival models. Therefore, this residual error structure was assumed for further analysis.
Measurement variability
Plasma concentrations for each horse were chemically analysed in duplicate at each time point. We therefore explored whether significant measurement error existed in the data. Measurement variability was accounted for by including a random effect on each individual parameter (i.e. Cl i , F Ei and V i ). Table 2 shows the median deviance values for models fitted with and without MEV. As can be seen, there was a reduction in the median deviance when MEV was included. However, it is unclear whether this is significant given the extra number of estimable parameters introduced into the model. Hence, the deviance information criterion (DIC) was used to compare the two models . The information criterion is as follows.
where 
Covariate modelling
Covariate relationships were initially investigated through the use of scatter plots against individual parameters. If any of the relationships warranted further investigation, then models with these covariate relationships were fitted. Limited data were available, so results from this part of the analysis should be treated with caution. 1977 1951, 2008 The covariate plots can be seen for HEPS in Fig. 4 . There did not appear to be a relationship between any covariates and the estimates of individual parameters except for log V i and median horse weight (Fig. 4c) . That is, it appeared that as the horse weight increased, log V i also increased. The plot also suggests that the relationship (if it exists) could be linear. As such, the (median) weight of each horse was included in the model as follows:
where w i is the weight of the ith horse and 548 is the median weight over all horses. The results from the fit where weight was included as a covariate on log V are given in Table 2 . As can be seen, there was no reduction in the median deviance of the model with weight, compared with the model without weight. However, this is not the full picture as it is possible for a covariate to be significant without there being a significant reduction in deviance. Therefore, we explored other indicators such as whether the BSV on log V had been reduced and whether the credible interval for b 2 (from above) included zero or not.
The posterior distribution of b 2 was examined, and it was found that zero was a highly probable value. Further, the BSV of log V without weight in the model was 0.0729, while with weight, this reduced to 0.0709, reduction of about 3%. Given this, it was concluded that weight was not significant, and therefore, it was not included into the final model.
Model fit
The individual fits to the data can be seen for plasma concentrations in Fig. 5 and cumulative urine amounts in Fig. 6 . The individual fits for plasma concentrations are represented by two lines corresponding to duplicate measurements taken on each blood sample as the MEV was found to be significant. In some horses, this is difficult to see, but is particularly visible for horses 4 and 5. All individual specific models seemed to fit the data well. The same was true for the individual cumulative urine fits.
A summary of parameter estimates (posterior medians) for the final model is given in Table 3 . The large estimate of k 12 shows a rapid rate of conversion from ACP to HEPS. The clearance rate of HEPS was 769 L/h with a volume of distribution of 6874 L (both scaled by the fraction of parent converted to metabolite). The BSV of Cl, F E and V is small, at around 30%. No estimate for the BSV of k 12 is given as this was considered as a fixed effect in the model. Figure 7 shows the residual error plots for the final model. The standardized residuals are given for both responses. For plasma concentrations, all plots appear reasonable given the assumption of normally distributed residuals. The QQ plot shows discrepancy between the standardized residuals and the fitted normal density at the lower tail, but this was not deemed significant. Similarly, the residual plots for cumulative urine amounts generally do not violate the assumption for normality. Again, discrepancies appear in the QQ plot, but at both tails.
Model checking and validation
Posterior predictive checks were used to determine whether the model developed was consistent with the data. The checks were performed in the following way. After fitting the final model, each parameter has a posterior distribution. This distribution summarizes the uncertainty about the estimate (given the prior and the observed data). Ten thousand random samples were drawn from the posterior distribution, and the concentration (lg/L) at time t hours was simulated (based on each of the 10 000 random samples). This produced a distribution of concentrations (lg/L) at each time point considered. The 5th, 50th and 95th percentiles of these distributions can be seen in Fig. 8 , with the observed data as dots. The two extreme percentiles reflect the uncertainty about the estimated concentrations.
The plots show that some of the observations fall outside the percentiles. This is to be expected, as in theory approximately 10% of the data points should fall outside the limits given by the 90% credible interval. For the plasma concentrations, the uncertainty below the median seems to increase with time. This is not surprising given that less data were available at later time points as the concentrations of HEPS in some samples fell below the LOD. Further, the plot is on the log-scale, so these actually relate to very low concentrations.
For the urine data, the upper bound of the 90% credible intervals extends noticeably higher than the observed data. This suggests that BSV and/or MEV may be inflating estimates of F E leading to a larger than expected amount of HEPS being excreted renally. Thus, detection times may be longer than expected. Overall, both posterior predictive checks seem consistent with the observed data.
Withholding and detection times
The detection time for a therapeutic substance represents the period after administration that the laboratories can identify the substance or its metabolite in either blood or urine. The withholding time is usually judged by a veterinarian and represents the period between drug administration and a race, taking into account the published detection time and a number of other factors.
Toutain ( concentration ratio parameter. An important feature of this research was the identification of the most influential parameters through a sensitivity analysis. This revealed that the manner in which the body processed the compound determines the detection time rather than, for example, dose.
Given we have undertaken a full compartmental analysis under a Bayesian framework, we provide an alternative approach for the estimation of withholding times. This approach will allow withholding times to be estimated from both plasma and urine samples and allows for the practical consideration that a horse will empty their bladder.
Probability of detection in plasma. Suppose we are interested in determining how likely it is for a horse to have a HEPS concentration in plasma greater than, say, the LOD of 1 lg/L at a certain time t after being given an intravenous bolus dose of 30 mg of ACP. Given the population model developed in this research, this can be resolved by considering the simulated data from the posterior predictive check. In the posterior predictive check, random samples are drawn from the posterior distribution of parameters and data generated for some time points (t). Thus, the probability of a horse having a HEPS concentration greater than, say, the LOD at time t can be determined from the simulated data. For a given time t, the number of simulated observations that are greater than the LOD is simply counted, then divided by the total number of simulated observations at that particular time (t). This provides an estimate for the probability that a concentration will be larger than the LOD. A plot of these estimated probabilities can be seen in Fig. 9 . Figure 9 shows three plots. Figure 9a shows the estimated probabilities of detection based on the population estimates of parameters and therefore represents estimates for a typical horse in the sample. Alternatively, Fig. 9b shows the estimated probabilities of detection for the individual horses in the study. The second plot shows how the probability of detection varies among individual horses. This highlights the potential for extreme detection probabilities for specific horses and the sensitivity of the estimates to the horses studied. The last plot is an empirical estimate of a survivor type function. The plot shows the estimates (with 95% confidence bounds) of the probability that a detection time is larger than some time t. For example, it shows that at 30 h after ACP administration, while 10% of the horses would be expected to have a concentration of HEPS in plasma greater than the LOD, in practice this percentage may be as small as 0% or as large as 25%.
Probability of detection in urine. Assume we are interested in determining how likely it is for a horse to have a HEPS concentration in urine greater than, say, the LOD of 1 lg/L at a certain time (t) after being given an intravenous bolus dose of 30 mg of ACP. The model for HEPS given in section 'Model' predicts the accumulated urine amount of HEPS at a given time t. In order to determine detection times, an estimate of urine volume or accumulated urine volume at time t needs to be made. Figure 10 shows the observed cumulative urine volumes for all horses against time. A strong linear relationship is evident between cumulated volume and time, with the variability in the response increasing with time. Therefore, a linear mixed effects model with proportional residual error was fitted to the cumulative urine volume with time as the independent variable. Further details are given in Appendix A. It is now possible to predict the cumulative amount of HEPS and cumulative urine volume for a given time t. Given that detection in urine is based on the concentration, these cumulative predictions need to be combined and converted to concentrations. One solution is to consider, say, 4-h windows from the time of drug administration, and the amount of HEPS and urine volume accumulated in these windows can be used to predict concentration. This approach assumes the following.
• The sample is representative of the population.
• The model developed describes the population.
• A linear relationship exists between urinary excretion rate of HEPS and the production rate of urine.
• The urinary production and excretion rate on race day (and/or days before race day) are the same as production and excretion rates during the study.
• The bladder is completely emptied at the beginning of each 4-h interval.
• Urine is collected at the end of a window.
Data were simulated from the cumulative urine amount and volume models, and the probability of detection was estimated in the same way as plasma (described above). Results can be seen in Fig. 11 .
Again, Fig. 11 shows three plots. Figure 11a shows the estimated probability of detection in urine given a 4-h window for a typical horse in the sample. The plot shows that there is quite a small probability of detection past 50 h, for example. This agrees well with the observed and predicted data shown in Fig. 8b as it appears that very little HEPS is accumulated in urine past this point in time. Figure 11b shows the estimated probabilities of detection based on individual estimates of PK parameters. These estimates relate to the individual horses in the study. The final plot shows an empirical estimate of a survivor type function. Detection times longer than 70 h appear rare given our best estimate. However, when calculating appropriate withholding times, the uncertainty around this estimate should also be considered. Thus, while only 10% of horses might be expected to breech the detection level at 65 h, this estimate could be between 0% and 25% for an individual horse.
CONCLUSION
A BHM was considered for the description of the metabolism of the parent-metabolite process for ACP. Given the half-life of ACP is much smaller than that of the metabolite, the model was reducible to the consideration of the metabolite only. The structural form of this model for the description of metabolite concentration in plasma and cumulative amount in urine was based on mass balance with vague priors chosen for the estimable parameters. No covariates were found to be statistically significant. This may be attributed to the small sample of horses measured and/or relatively narrow ranges of potential covariates, particularly for weight. Measurement variability on plasma concentrations proved to be influential, and random effects were included in the model to account for this.
Simulation techniques were used to show agreement between predicted and observed data and in the estimation of detection times for a typical horse in the sample. Detection in urine was complicated by the need to allow the horses to empty their bladder at various times after ACP had been administered. This was resolved by considering urine concentration in 4-h windows (postdose). Care should be taken when interpreting these results as the probability profiles are likely to change if different sized windows are considered. Nevertheless, the results shown should provide guidance for trainers and veterinarians to estimate appropriate withholding times to ensure that horses are not racing with prohibited substances in their system.
All inferences in this study were based on a sample of twelve horses. In making decisions in the model-building phase and providing estimates of, for example, clearance and withholding times, we assume that this sample is representative of the entire population. Indeed, in the selection of covariates, weight seemed somewhat linearly related to the volume of distribution. This relationship did not prove to be statistically significant, but this may have been due to the small sample size. Hence, care should be taken when drawing any inferences from this work.
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APPENDIX: MODEL FOR CUMULATIVE URINE VOLUME
The individual fits can be seen in Fig. A1 . From the plot, the proposed model seems to fit the observed data well for all horses. The residual plots and posterior predictive check can be seen in Figs A2 & A3, respectively. The posterior predictive check also shows the 90% credible interval for the predicted response. The QQ plot, histogram and observed vs. predicted plots show that the residuals generally follow a normal distribution. There is a slight pattern in the residual vs. predicted plot, but this was not deemed strong enough to violate our assumption about the residuals. The posterior predictive check shows agreement between the simulated and observed data and shows that some observations lie outside the 90% credible interval.
